Leveraging fluid dynamics characterization to accelerate cell therapy product development

Tuesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Leveraging fluid dynamics characterization to accelerate cell therapy product development

Discover how characterizing fluid dynamics (FD) improves cell therapy manufacturing by enabling higher cell yields, improved transduction efficiency, and reduced processing times. This webinar will showcase how the flexible mixing modes of a next-generation CGT platform enable customizable, scalable manufacturing processes that adapt to therapeutic needs and accelerate product development.

Attendees will learn on how FD insights guide the optimization of activation and transduction mixing parameters, resulting in enhanced biological performance and consistent, reliable batch-to-batch outcomes. Additionally, attendees will gain a deeper understanding of how engineering precision and fully closed design of a next-gen CGT platform eliminate manual interventions, reduce human error, and shorten manufacturing timelines by up to 25%, while minimizing the use of costly viral vectors.

The speakers will present actionable case studies, demonstrating how early adoption of automation supports faster process development and future scalability. Further, they will discuss how to apply FD data from the next-gen CGT platform to refine manufacturing processes, determine optimal conditions for cell growth and transduction, and identify opportunities to automate and close manual process steps to drive better therapeutic performance.

Attend this webinar to:

Learn how early automation integration reduces manual labor, eliminates tubing, bags, and pumps, traditional hardware, and shortens manufacturing timelines by up to 25%
Understand how flexible mixing modes and FD-driven optimization can improve yield, transduction efficiency, and overall biological performance
Explore real-world case studies that provide insights into optimizing manufacturing processes, achieve higher cell yields, improve transduction efficiency, and deliver consistent batch-to-batch performance

Hamza Patel

Senior Scientist at Ori Biotech

Dr Hamza Patel is a Senior Scientist at Ori Biotech, focusing on developing innovative manufacturing technologies for cell and gene therapies. With an EngD in Biochemical Engineering from University College London (UCL), he brings expertise in engineering solutions to complex biological challenges. Dr Patel is committed to driving down the cost of cell and gene therapies to make these life-changing treatments more accessible to patients.

Tom Heathman

Chief Commercial Officer at Ori Biotech

Tom currently serves as the Chief Commercial Officer for Ori Biotech, responsible for commercial launch of Ori’s technology, the IRO Platform, including deployments to initial customer base of Pharma and CDMOs. Prior to this, Tom served as the Business Leader for North America for Minaris Regenerative Medicine, a leading CDMO for the ATMP industry. During his time with Minaris, he led the growth of the North America business including the signing of commercial manufacturing agreements with leading therapy developers. Tom has a PhD in Cell and Gene Therapy Manufacturing from Loughborough University in the UK.